美国 - 英文 - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - finasteride (unii: 57gno57u7g) (finasteride - unii:57gno57u7g) - finasteride tablets, usp are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: - improve symptoms - reduce the risk of the need for surgery including transurethral resection of the prostate (turp) and prostatectomy. finasteride tablets, usp administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of bph (a confirmed ≥ 4 point increase in american urological association (aua) symptom score). finasteride tablets, usp are not approved for the prevention of prostate cancer.   finasteride tablets, usp is contraindicated in the following: - hypersensitivity to any component of this medication. - pregnancy. finasteride use is contraindicated in women when they are or may potentially be pregnant. because of the ability of type ii 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (dht), finasteride may cause abnormalities of the external genitalia of

南非 - 英文 - South African Health Products Regulatory Authority (SAHPRA)

zydus healthcare (pty) ltd - capsules - see ingredients - each capsule contains dutasteride 0,5 mg

马耳他 - 英文 - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - dutasteride - soft capsule - dutasteride 0.5 mg - urologicals

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

generics (uk) limited - dutasteride - capsules, soft - 0.5 milligram - testosterone-5-alpha reductase inhibitors

马耳他 - 英文 - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - dutasteride - soft capsule - dutasteride 0.5 mg - urologicals

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - dutasteride - capsule, soft - 0.5 milligram(s) - testosterone-5-alpha reductase inhibitors; dutasteride

美国 - 英文 - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - finasteride (unii: 57gno57u7g) (finasteride - unii:57gno57u7g) - finasteride 1 mg - finasteride tablets are indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men only . efficacy in bitemporal recession has not been established. finasteride tablets are not indicated for use in women. finasteride is contraindicated in the following: pregnancy category x [see contraindications (4)]. finasteride is contraindicated for use in women who are or may become pregnant. finasteride is a type ii 5α-reductase inhibitor that prevents conversion of testosterone to 5α-dihydrotestosterone (dht), a hormone necessary for normal development of male genitalia. in animal studies, finasteride caused abnormal development of external genitalia in male fetuses. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the male fetus. abnormal male genital development is an expected consequence when conversion of testosterone to 5α-dihydrotestosterone (dht) is inhibited by 5α-reductase inhibi

美国 - 英文 - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - dutasteride (unii: o0j6xjn02i) (dutasteride - unii:o0j6xjn02i) - dutasteride 0.5 mg - dutasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men with an enlarged prostate to: dutasteride in combination with the alpha adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic bph in men with an enlarged prostate. dutasteride is not approved for the prevention of prostate cancer. dutasteride is contraindicated for use in: pregnancy category x. dutasteride is contraindicated for use in women of childbearing potential and during pregnancy. dutasteride is a 5 alpha-reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (dht), a hormone necessary for normal development of male genitalia. in animal reproduction and developmental toxicity studies, dutasteride inhibited normal development of external genitalia in male fetuses. therefore, dutasteride may cause fetal harm when administered to a pregnant woman. if dutasteride is used during pregnancy or if the patient becomes pregnant while taking dutasteride, the

美国 - 英文 - NLM (National Library of Medicine)

merck sharp & dohme corp. - finasteride (unii: 57gno57u7g) (finasteride - unii:57gno57u7g) - finasteride 1 mg - propecia® is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men only . efficacy in bitemporal recession has not been established. propecia is not indicated for use in women. propecia is contraindicated in the following: - pregnancy. finasteride use is contraindicated in women when they are or may potentially be pregnant. because of the ability of type ii 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (dht), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant woman who receives finasteride. if this drug is used during pregnancy, or if pregnancy occurs while taking this drug, the pregnant woman should be apprised of the potential hazard to the male fetus. [see warnings and precautions (5.1), use in specific populations (8.1), how supplied/storage and handling (16) and patient counseling information (17).] in female rats, low doses of finasteride administered during pregnancy have produced ab

美国 - 英文 - NLM (National Library of Medicine)

physicians total care, inc. - finasteride (unii: 57gno57u7g) (finasteride - unii:57gno57u7g) - finasteride 1 mg - propecia® is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men only . efficacy in bitemporal recession has not been established. propecia is not indicated for use in women. propecia is contraindicated in the following: - pregnancy. finasteride use is contraindicated in women when they are or may potentially be pregnant. because of the ability of type ii 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (dht), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant woman who receives finasteride. if this drug is used during pregnancy, or if pregnancy occurs while taking this drug, the pregnant woman should be apprised of the potential hazard to the male fetus. [see warnings and precautions (5.1), use in specific populations (8.1), how supplied/storage and handling (16) and patient counseling information (17.1).] in female rats, low doses of finasteride administered during pregnancy have produced